BioTelemetry Inc (NASDAQ:BEAT) Given Average Recommendation of “Buy” by Brokerages

Shares of BioTelemetry Inc (NASDAQ:BEAT) have been assigned an average rating of “Buy” from the nine research firms that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $67.00.

A number of equities analysts have weighed in on the company. SunTrust Banks reissued a “buy” rating and issued a $58.00 target price on shares of BioTelemetry in a research report on Wednesday, July 8th. Zacks Investment Research raised BioTelemetry from a “sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, BidaskClub lowered BioTelemetry from a “buy” rating to a “hold” rating in a research report on Friday, June 12th.

A number of institutional investors and hedge funds have recently modified their holdings of the business. APG Asset Management N.V. purchased a new position in BioTelemetry during the first quarter worth approximately $1,857,000. Geode Capital Management LLC raised its holdings in shares of BioTelemetry by 6.8% in the 1st quarter. Geode Capital Management LLC now owns 498,293 shares of the medical research company’s stock valued at $19,189,000 after buying an additional 31,893 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of BioTelemetry by 28.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 138,609 shares of the medical research company’s stock valued at $6,418,000 after buying an additional 30,811 shares during the period. Legal & General Group Plc raised its holdings in shares of BioTelemetry by 2.1% in the 1st quarter. Legal & General Group Plc now owns 283,490 shares of the medical research company’s stock valued at $12,412,000 after buying an additional 5,803 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ acquired a new position in BioTelemetry during the 1st quarter worth $1,071,000. 94.68% of the stock is currently owned by institutional investors.

Shares of NASDAQ:BEAT opened at $42.56 on Friday. BioTelemetry has a fifty-two week low of $27.35 and a fifty-two week high of $55.85. The business has a 50-day simple moving average of $43.53 and a two-hundred day simple moving average of $44.90. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.19 and a current ratio of 4.34. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of 81.85, a price-to-earnings-growth ratio of 2.85 and a beta of 1.30.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Thursday, July 30th. The medical research company reported $0.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.19. BioTelemetry had a return on equity of 17.87% and a net margin of 4.42%. The business had revenue of $99.11 million during the quarter, compared to analyst estimates of $85.93 million. As a group, research analysts predict that BioTelemetry will post 1.49 earnings per share for the current year.

About BioTelemetry

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

See Also: What are the benefits of a balanced fund?

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.